title: Follicular rash during therapy with erlotinib (Tarceva).
abstract: Erlotinib is a small-molecule tyrosine kinase inhibitor of the EGF receptor which has become an important oncological agent, used primarily in treating non-small-cell lung cancer. The most common side effects of this class of EGF receptor antagonists are cutaneous rashes. The severity of the skin rash seems to be correlated to clinical response and should be a motivating factor to continue therapy. We report a case of a patient who developed a follicular rash during therapy with erlotinib.
authors.affiliation: Clinic for Dermatology, Venerology and Allergology, University Clinic Schleswig-Holstein, Campus Kiel, Kiel, Germany. sgerdes@dermatology.uni-kiel.de
authors.forename: Sascha
authors.initials: S
authors.lastname: Gerdes
authors.forename: Ulrich
authors.initials: U
authors.lastname: Mrowietz
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D000069347:Erlotinib Hydrochloride; D005148:Facial Dermatoses / Q000139:chemically induced* / Q000473:pathology*; D005499:Folliculitis / Q000139:chemically induced* / Q000473:pathology*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011537:Pruritus / Q000139:chemically induced* / Q000175:diagnosis*; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride